Section Arrow
SNGX.NASDAQ
- Soligenix Inc.
(Financial Status)
Quotes are at least 15-min delayed:2025/09/05 13:57 EDT
Regular Hours
Last
 3
-0.04 (-1.32%)
Day High 
3.07 
Prev. Close
3.04 
1-M High
6.2299 
Volume 
147.08K 
Bid
2.96
Ask
3
Day Low
2.8809 
Open
3.07 
1-M Low
2.32 
Market Cap 
9.92M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.14 
20-SMA 3.15 
50-SMA 2.22 
52-W High 6.2299 
52-W Low 1.09 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.06/-1.49
Enterprise Value
9.92M
Balance Sheet
Book Value Per Share
0.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.31
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADAPAdaptimmune Therapeutics plc0.04859-0.00241-4.73%-- 
NUVBNuvation Bio3.94+0.52+15.20%-- 
IOVAIovance Biotherapeutics2.4+0.2+9.09%-- 
RXRXRecursion Pharmaceuticals4.575+0.055+1.22%-- 
MRNAModerna25.26+0.98+4.04%-- 
Quotes are at least 15-min delayed:2025/09/05 13:57 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.